This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Allscripts' (MDRX) Unit Inks Deal to Boost Clinical Research
by Zacks Equity Research
Allscripts' (MDRX) unit, Veradigm, enters into a strategic partnership with PRA Health (PRAH) to expand patients' access to clinical research.
Here's Why You Should Retain PRA Health (PRAH) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about PRA Health (PRAH) owing to its strategic alliances and solid CRO market prospects.
PRA Health's (PRAH) New Solution to Speed Up Drug Development
by Zacks Equity Research
PRA Health's (PRAH) tokenization solution can help in the generation of enhanced evidence for drug development through Synoma.
PRA Health (PRAH) Stock Down 0.3% Despite Q1 Earnings Beat
by Zacks Equity Research
PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the first quarter.
PRA Health Sciences (PRAH) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
PRA Health Sciences (PRAH) delivered earnings and revenue surprises of 0.75% and 9.22%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Sonos, Dollar General, PerkinElmer, PRA Health Sciences and Hologic highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Sonos, Dollar General, PerkinElmer, PRA Health Sciences and Hologic highlighted as Zacks Bull and Bear of the Day
PRA Health Sciences (PRAH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
PRA Health Sciences (PRAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MedTech M&A Scaling New Heights in 2021 on Rising Investor Wealth
by Urmimala Biswas
While smaller tuck-in acquisitions dominated the M&A space throughout 2020, 2021 is seeing a number of colossal deals.
PRA Health Sciences (PRAH) Surges 3.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
PRA Health Sciences (PRAH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
PRA Health (PRAH) Chosen by MedChi to Offer Telehealth Services
by Zacks Equity Research
PRA Health's (PRAH) company, Care Innovations, gets selected by MedChi to provide remote patient monitoring services, thereby enabling better patient care.
Merck KGaA Chooses PRA Health's (PRAH) Remote Monitoring Tool
by Zacks Equity Research
PRA Health's (PRAH) remote patient monitoring platform will enable Merck KGaA to offer patients an array of advanced tools to help manage their conditions.
Ecolab (ECL) Unveils Its Enhanced Smart Water Navigator
by Zacks Equity Research
Ecolab's (ECL) smart tool is expected to bridge the widening gap between freshwater supply and demand via efficient water management.
Why Is PRA Health Sciences (PRAH) Down 0.7% Since Last Earnings Report?
by Zacks Equity Research
PRA Health Sciences (PRAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PRA Health (PRAH) Unveils Toolkit for Rare Disease Patients
by Zacks Equity Research
PRA Health (PRAH) launches patient-focused toolkit to lower the burden on patients with rare diseases to participate in clinical research.
PRA Health (PRAH) Stock Down 2.8% Despite Q4 Earnings Beat
by Zacks Equity Research
PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the fourth quarter.
Company News for Feb 25, 2021
by Zacks Equity Research
Companies In The News Are: VCEL, LNG, HZNP, PRAH
PRA Health Sciences (PRAH) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
PRA Health Sciences (PRAH) delivered earnings and revenue surprises of 5.44% and 5.42%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
PRA Health Sciences (PRAH) Down 2.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
PRA Health Sciences (PRAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks Industry Outlook Highlights: Teladoc, PRA Health and DexCom
by Zacks Equity Research
Zacks Industry Outlook Highlights: Teladoc, PRA Health and DexCom
IoMT Meets New Healthcare Needs: 3 MedTech Trends to Watch
by Urmimala Biswas
Medical device which has for long taken tiny steps toward IoMT is now going all out to make the most of the advancements in this space amid the pandemic.
Improving Patient Volumes Aid Select Medical's (SEM) Prospects
by Zacks Equity Research
Recovery in patient volumes owing to relaxation of government-imposed constraints is gradually restoring the patient admissions, thereby reinstating Select Medical (SEM) on the growth path.
PRA Health (PRAH) Gains 4.3% Following Q3 Earnings Beat
by Zacks Equity Research
PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the third quarter.
PRA Health Sciences (PRAH) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
PRA Health Sciences (PRAH) delivered earnings and revenue surprises of 15.04% and 3.71%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate PRA Health Sciences (PRAH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
PRA Health Sciences (PRAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Beaten-Down MedTech Stocks to Grab Amid Market Meltdown
by Sriparna Ghosal
These cheap MedTech stocks are currently flourishing on the back of a number of positive developments.